Inspire Investing’s BioCryst Pharmaceuticals BCRX Stock Holding History

Inspire Investing’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$690K	Buy	68,979 +15,100	+28%	+$137K	0.03%	537
2026 Q1	$513K	Sell	53,879 -6,170	-10%	-$47.9K	0.03%	734
2025 Q4	$468K	Buy	60,049 +124	+0.2%	+$896	0.04%	473
2025 Q3	$455K	Buy	59,925 +16,716	+39%	+$139K	0.04%	517
2025 Q2	$387K	Sell	43,209 -2,692	-6%	-$25.1K	0.04%	672
2025 Q1	$344K	Sell	45,901 -7,578	-14%	-$61.1K	0.04%	491
2024 Q4	$402K	Sell	53,479 -104,529	-66%	-$794K	0.05%	450
2024 Q3	$1.2M	Buy	158,008 +100,458	+175%	+$764K	0.12%	178
2024 Q2	$356K	Sell	57,550 -11,916	-17%	-$65.8K	0.04%	396
2024 Q1	$353K	Buy	69,466 +6,141	+10%	+$34.5K	0.04%	782
2023 Q4	$379K	Buy	63,325 +20,255	+47%	+$117K	0.04%	772
2023 Q3	$305K	Sell	43,070 -1,513	-3%	-$10.9K	0.04%	747
2023 Q2	$314K	Buy	44,583 +12,234	+38%	+$98.2K	0.04%	590
2023 Q1	$270K	Buy	32,349 +11,559	+56%	+$111K	0.03%	767
2022 Q4	$239K	Buy	20,790 +4,402	+27%	+$54.9K	0.03%	367
2022 Q3	$206K	Buy	+16,388	New	+$211K	0.03%	593

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Inspire Investing's BCRX Position: Q2 2026 in Review

Inspire Investing increased its BioCryst Pharmaceuticals (BCRX) stake by 28% in Q2 2026, buying an estimated $137K and bringing the position to 68,979 shares worth $690K. The position accounts for 0.03% of the portfolio, ranked #537.

Inspire Investing first reported a position in BCRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.2M in Q3 2024. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Inspire Investing held 68,979 shares of BioCryst Pharmaceuticals worth $690K as of Q2 2026.
Inspire Investing bought 15,100 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $137K.
BioCryst Pharmaceuticals made up 0.03% of Inspire Investing's portfolio in Q2 2026, its #537 holding.
Inspire Investing first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Inspire Investing's BioCryst Pharmaceuticals position peaked at $1.2M in Q3 2024.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.